Tag: OTCQB:BCTXF

August 12, 2019

BriaCell Appoints Richard J. Berman to Board of Directors

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast...
July 23, 2019

BriaCell Announces $350,000 Equity Investment by Board of Directors

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast...
May 28, 2019

BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast...
May 27, 2019

BriaCell Pioneering Immunotherapy For Advanced Breast Cancer Treatment

BriaCell Therapeutics (TSX:BCT, OTCQB:BCTXF) CEO Dr. Bill Williams was recently featured in an article by BioTuesdays outlining the company's progress in...
May 24, 2019

BriaCell’s Immunotherapy Technology Featured in The Financial Post

BriaCell Therapeutics (TSXV:BCT) (OTCQB:BCTXF) has been featured in a paid advertisement published in The Financial Post.
May 17, 2019

Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.

Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics...
May 13, 2019

BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that...